Show simple item record

dc.rights.licenseopenen_US
hal.structure.identifierHôpital Henri Mondor
hal.structure.identifierFondation FondaMental [Créteil]
hal.structure.identifierIMRB - "Neuropsychiatrie translationnelle" [Créteil] [U955 Inserm - UPEC]
dc.contributor.authorFOISELLE, Marianne
hal.structure.identifierInstitut de pharmacologie moléculaire et cellulaire [IPMC]
dc.contributor.authorBARBOSA, Susana
hal.structure.identifierHôpital Henri Mondor
hal.structure.identifierFondation FondaMental [Créteil]
hal.structure.identifierIMRB - "Neuropsychiatrie translationnelle" [Créteil] [U955 Inserm - UPEC]
dc.contributor.authorGODIN, Ophelia
dc.contributor.authorWU, C.-L.
dc.contributor.authorBOUKOUACI, W.
hal.structure.identifierCentre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
hal.structure.identifierFondation FondaMental [Créteil]
dc.contributor.authorANDRE, Myrtille
hal.structure.identifierFondation FondaMental [Créteil]
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorAOUIZERATE, Bruno
hal.structure.identifierNeuropsychologie Cognitive et Physiopathologie de la Schizophrénie [NCPS]
hal.structure.identifierFondation FondaMental [Créteil]
dc.contributor.authorBERNA, Fabrice
dc.contributor.authorBARAU, C.
hal.structure.identifierCentre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
hal.structure.identifierFondation FondaMental [Créteil]
dc.contributor.authorCAPDEVIELLE, Delphine
hal.structure.identifierNeuropsychologie Cognitive et Physiopathologie de la Schizophrénie [NCPS]
hal.structure.identifierFondation FondaMental [Créteil]
dc.contributor.authorVIDAILHET, Pierre
hal.structure.identifierFondation FondaMental [Créteil]
hal.structure.identifierNeuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux [NPsy-Sydo]
dc.contributor.authorCHEREAU, Isabelle
hal.structure.identifierInstitut de pharmacologie moléculaire et cellulaire [IPMC]
dc.contributor.authorDAVIDOVIC, Laetitia
dc.contributor.authorDOREY, J.-M.
dc.contributor.authorDUBERTRET, C.
dc.contributor.authorDUBREUCQ, J.
dc.contributor.authorFAGET, C.
dc.contributor.authorLEIGNER, S.
dc.contributor.authorLLORCA, P.-M.
dc.contributor.authorMALLET, J.
dc.contributor.authorMISDRAHI, D.
dc.contributor.authorMARTINUZZI, E.
dc.contributor.authorPASSERIEUX, C.
dc.contributor.authorREY, R.
dc.contributor.authorURBACH, M.
hal.structure.identifierFondation FondaMental [Créteil]
dc.contributor.authorSCHURHOFF, Franck
dc.contributor.authorGLAICHENHAUS, N.
dc.contributor.authorLEBOYER, M.
dc.contributor.authorTAMOUZA, R.
dc.contributor.authorHAFFEN, E.
dc.contributor.authorBARTEAU, V.
dc.contributor.authorBENSALEM, S.
dc.contributor.authorLAOUAMRI, H.
dc.contributor.authorSOURYIS, K.
dc.contributor.authorOFFERLIN-MEYER, I.
dc.contributor.authorPIGNON, B.
dc.contributor.authorSZÖKE, A.
dc.contributor.authorDELOGE, A.
dc.contributor.authorMISDRAHI, D.
dc.contributor.authorVILÀ, E.
dc.contributor.authorBLANC, O.
dc.contributor.authorDENIZOT, H.
dc.contributor.authorHONCIUC, R.M.
dc.contributor.authorLACELLE, D.
dc.contributor.authorPIRES, S.
dc.contributor.authorPORTALIER, C.
dc.contributor.authorDUBREUCQ, J.
dc.contributor.authorFLUTTAZ, C.
dc.contributor.authorGABAYET, F.
dc.contributor.authorROMAN, C.
dc.contributor.authorCHESNOY-SERVANIN, G.
dc.contributor.authorD'AMATO, T.
dc.contributor.authorVEHIER, A.
dc.contributor.authorLANÇON, C.
dc.contributor.authorMETAIRIE, E.
dc.contributor.authorPERI, P.
dc.contributor.authorVAILLANT, F.
dc.contributor.authorBOYER, L.
dc.contributor.authorFOND, G.
dc.contributor.authorZINETTI-BERTSCHY, A.
dc.contributor.authorYAZBEK, H.
dc.contributor.authorESSELIN, S.
dc.contributor.authorJARROIR, M.
dc.contributor.authorURBACH, M.
dc.date.accessioned2023-01-04T15:53:51Z
dc.date.available2023-01-04T15:53:51Z
dc.date.issued2022-07
dc.identifier.issn2666-3546en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/171604
dc.description.abstractEnBackground: Metabolic syndrome (MetS) is a highly prevalent and harmful medical disorder often comorbid with psychosis where it can contribute to cardiovascular complications. As immune dysfunction is a key shared component of both MetS and schizophrenia (SZ), this study investigated the relationship between immune alterations and MetS in patients with SZ, whilst controlling the impact of confounding clinical characteristics including psychiatric symptoms and comorbidities, history of childhood maltreatment and psychotropic treatments. Method: A total of 310 patients meeting DSM-IV criteria for SZ or schizoaffective disorders (SZA), with or without MetS, were systematically assessed and included in the FondaMental Advanced Centers of Expertise for Schizophrenia (FACE-SZ) cohort. Detailed clinical characteristics of patients, including psychotic symptomatology, psychiatric comorbidities and history of childhood maltreatment were recorded and the serum levels of 18 cytokines were measured. A penalized regression method was performed to analyze associations between inflammation and MetS, whilst controlling for confounding factors. Results: Of the total sample, 25% of patients had MetS. Eight cytokines were above the lower limit of detection (LLOD) in more than 90% of the samples and retained in downstream analysis. Using a conservative Variable Inclusion Probability (VIP) of 75%, we found that elevated levels of interleukin (IL)-6, IL-7, IL-12/23 p40 and IL-16 and lower levels of tumor necrosis factor (TNF)-α were associated with MetS. As for clinical variables, age, sex, body mass index (BMI), diagnosis of SZ (not SZA), age at the first episode of psychosis (FEP), alcohol abuse, current tobacco smoking, and treatment with antidepressants and anxiolytics were all associated with MetS. Conclusion: We have identified five cytokines associated with MetS in SZ suggesting that patients with psychotic disorders and MetS are characterized by a specific “immuno-metabolic” profile. This may help to design tailored treatments for this subgroup of patients with both psychotic disorders and MetS, taking one more step towards precision medicine in psychiatry. © 2022 The Authors
dc.description.sponsorshipImmuno-Génétique, Inflammation, retro-Virus, Environnement : de l'étiopathogénie des troubles psychotiques aux modèles animauxen_US
dc.description.sponsorshipRéseau d'Innovation sur les Voies de Signalisation en Sciences de la Vieen_US
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enMetabolic syndrome
dc.subject.enSchizophrenia
dc.subject.enPsychosis
dc.subject.enInflammation
dc.subject.enMachine learning
dc.subject.enPrecision medicine
dc.title.enImmuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.bbih.2022.100436en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed35469211en_US
bordeaux.journalBrain, Behavior, and Immunity - Healthen_US
bordeaux.volume22en_US
bordeaux.hal.laboratoriesNutriNeurO (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINRAEen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDFondation FondaMentalen_US
hal.exportfalse
dc.rights.ccCC BY-NC-NDen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Brain,%20Behavior,%20and%20Immunity%20-%20Health&rft.date=2022-07&rft.volume=22&rft.eissn=2666-3546&rft.issn=2666-3546&rft.au=FOISELLE,%20Marianne&BARBOSA,%20Susana&GODIN,%20Ophelia&WU,%20C.-L.&BOUKOUACI,%20W.&rft.genre=article


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record